Proteus mirabilis (ATCC 29906), Pyelonephritis (Kidney Infection) Model, CFU data
CONTACT CUSTOMER SERVICE
ADD TO FAVORITES
ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This assay is used to assess the antimicrobial efficacy of test articles in a murine model of complicated urinary tract infection model using neutropenic mice. Pathogen is injected directly into the kidney tissue, antimicrobial agent is administered then the change in pathogen load is measured following a 24 h treatment period. The pyelonephritis model has been established with diverse Enterobacteriaceae including susceptible and multidrug resistant strains of E. coli, K. pneumoniae, E. cloacae, and P. mirabilis to enable testing of organisms with varied antibiotic susceptibility and resistance mechanisms.
SPECIES
Proteus mirabilis
STRAIN COMMON NAME
ATCC 29906
ORGANISM
Gram-negative Bacteria
GENOMIC ACCESSION NUMBER
AF008582
SOURCE
STRAIN SOURCE
American Type Culture Collection (ATCC)
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 5 female specific-pathogen-free ICR (CD-1) neutropenic mice are directly inoculated with pathogen suspension into kidneys. Vehicle and/or test substances are then administered by IV, IP, SC, or PO administration (or per client's request) starting at 2 hours after infection. At 24 hours after the first treatment, animals are humanely euthanized and both kidneys are harvested from each test animal. The collected kidneys are homogenized and pathogen counts are determined by dilution plating technique.
CRITERIA FOR SIGNIFICANCE
A significant (p < 0.05) decrease in the bacterial counts of the treated animals compared to the vehicle control group or the baseline control group is considered a significant difference.
TURNAROUND TIME
STANDARD
20 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.
ITEM DOES NOT EXIST
© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences